Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (256)	7/16/2003 7:56:17 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 590

They did not say is this second antibody for second target or new antibody for old target. What is going on with first antibody? Press Release Source: Abgenix Abgenix to Receive IND Milestone Payment from Pfizer Wednesday July 16, 8:16 am ET FREMONT, Calif.--(BUSINESS WIRE)--July 16, 2003--Abgenix, Inc. (Nasdaq:ABGX - News) announced today that the company will receive a milestone payment from Pfizer (NYSE:PFE - News) triggered by Pfizer's filing of an Investigational New Drug application with the FDA. The IND filing by Pfizer represents the second antibody product candidate to enter clinical studies from the companies' ongoing antibody research collaboration.<snip>